Key result
Antianginal drug therapy should be individualized based on resting heart rate, blood pressure, hemodynamic status, and comorbidities to minimize cardiac adverse effects.
Why the study?
What are the cardiac adverse effects of antianginal drugs and how can they be minimized in patients with angina?
What are the cardiac adverse effects of antianginal drugs and how can they be minimized in patients with angina?
Antianginal therapy should be individualized based on patient hemodynamics, LV function, and comorbidities to minimize cardiac adverse effects.
INTRODUCTION: Angina pectoris is a common presenting symptom of underlying coronary artery disease or reduced coronary flow reserve. Patients with angina have impaired quality of life; and need to be treated optimally with antianginal drugs to control symptoms and improve exercise performance. A wide range of antianginal medications are approved for the treatment of angina, and often more than one class of antianginal drugs are used to adequately control the symptoms. This expert opinion highlights the likely cardiac adverse effects of available antianginal drugs, and how to minimize these in individual patients and especially during combination treatment. Areas covered: All approved antianginal drugs, including the older and newly approved medications with different mechanism of action to the older drugs as well as some of the unapproved herbal medications. The safety profiles and potential cardiac side effects of these medications when used as monotherapy or as combination therapy are discussed and highlighted. Expert opinion: Because of the different cardiac safety profiles and possible side effects, we recommend selection of initial drug or adjustment of therapy based on the resting heart rate; blood pressure, hemodynamic status; and resting left ventricular function, concomitant medications and any associated comorbidities.
No takes yet. Share an insight, caveat, or question.
Rousan et al. (2016) conducted a review in Angina pectoris. Antianginal drugs was evaluated. Antianginal drug therapy should be individualized based on resting heart rate, blood pressure, hemodynamic status, and comorbidities to minimize cardiac adverse effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: